Researchers found that patients with type 2 diabetes and a recent acute coronary syndrome who received alogliptin did not have an increased risk of either first or recurrent cardiovascular events, compared with those on placebo. The findings in Clinical Cardiology, based on 5,380 patients from the Examination of Cardiovascular Outcomes with Alogliptin vs Standard of Care trial, revealed no significant difference in the number or type of CV events between the two groups.
Alogliptin does not raise CV event risk in diabetes, ACS patients, study finds
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.